This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campo, E. Articles by Yague, J. Search for Related Content PubMed PubMed Citation Articles by Campo, E. Articles by Yague, J.

Loss of Heterozygosity of p53 Gene and p53 Protein Expression in Human Colorectal Carcinomas¹

Departments of Pathology [E. C., R. M., A. P., A. C.] and Immunology [O. C-M., M. R., V. F., J. V., J. Y.], Hospital Clinico y Provincial, School of Medicine, University of Barcelona, Calle Villarroel 170, E-08036 Barcelona, Spain

The p53 gene is a tumor suppressor gene located on chromosome 17p. Deletions of this chromosome and point mutations of p53 have been implicated in the development of colonic neoplasms. We have analyzed the loss of heterozygosity of the human p53 tumor suppressor gene in 40 cases of colorectal carcinoma using two restriction fragment length polymorphisms detected by Bg/II and AccII restriction enzymes. p53 gene product expression was studied immunohistochemically in 64 colorectal carcinomas, 18 adenomas, and 40 normal colonic mucosae using an anti-human p53 monoclonal antibody (Pab 1801) and the avidinbiotin-peroxidase complex technique. Twelve of the 40 patients (30%) were polymorphic for the p53 gene. In ten of these informative patients (83%), the tumor samples showed the loss of one allele when compared with normal colorectal samples of the same patient. One of the homozygous patients showed a loss of both p53 alleles. p53 immunostaining was observed in 43 of 64 carcinomas (67%) but only in two adenomas (11%). These two positive adenomas showed areas of carcinoma in situ. The normal mucosa was always negative. No relation could be found between p53 immunostaining and the degree of differentiation, the extension of the tumor, or the Ki-67 proliferative index. Mucinous carcinomas and right-side carcinomas were less p53 immunoreactive (25% and 52%, respectively) than the usual adenocarcinomas (73%) and distal tumors (72%). These findings suggest that p53 may be a target of chromosome 17 deletions and that this gene may play a role in the malignant transformation of adenomas. Bg/II and AccII restriction fragment length polymorphism analysis of the p53 gene may be a useful and direct technique to detect allelic loss of this gene in tumors.

¹ This study was supported by Grants CAICIT PB 86/0046 (J. Y.) and DGICYT PM 90/0060 (E. C.) from the Spanish Ministerio de Educacion y Ciencia. R. M. and O. C-M. were fellows supported by the Spanish Ministerio de Educacion y Ciencia and Hospital Clinico y Provincial de Barcelona, respectively.

² To whom requests for reprints should be addressed.

Received 10/ 8/90. Accepted 5/31/91.

This article has been cited by other articles:

				J. G. Einspahr, M. E. Martinez, R. Jiang, C.-H. Hsu, A. K. Bhattacharrya, D. J. Ahnen, E. T. Jacobs, P. S. Houlihan, C. R. Webb, D. S. Alberts, et al. Associations of Ki-ras Proto-oncogene Mutation and p53 Gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1443 - 1450. [Abstract] [Full Text] [PDF]

				S. Ikeda, Y. Shimizu, M. Fujimori, Y. Ishizaki, T. Kurihara, Y. Ojima, M. Okajima, and T. Asahara Immunohistochemical and Mutational Analyses of {beta}-catenin, Ki-ras, and p53 in Two Subtypes of Colorectal Mucinous Carcinoma Clin. Cancer Res., November 15, 2003; 9(15): 5660 - 5665. [Abstract] [Full Text] [PDF]

				K. Ookawa, T. Kudo, S. Aizawa, H. Saito, and S. Tsuchida Transcriptional Activation of the MUC2 Gene by p53 J. Biol. Chem., December 6, 2002; 277(50): 48270 - 48275. [Abstract] [Full Text] [PDF]

				K. Matsuda, T. Masaki, T. Watanabe, J. Kitayama, H. Nagawa, T. Muto, and Y. Ajioka Clinical Significance of MUC1 and MUC2 Mucin and p53 Protein Expression in Colorectal Carcinoma Jpn. J. Clin. Oncol., February 1, 2000; 30(2): 89 - 94. [Abstract] [Full Text] [PDF]

				K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al. Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers J Natl Cancer Inst, August 4, 1999; 91(15): 1295 - 1303. [Abstract] [Full Text] [PDF]

				S. Bea, M. Ribas, J. M. Hernandez, F. Bosch, M. Pinyol, L. Hernandez, J. L. Garcia, T. Flores, M. Gonzalez, A. Lopez-Guillermo, et al. Increased Number of Chromosomal Imbalances and High-Level DNA Amplifications in Mantle Cell Lymphoma Are Associated With Blastoid Variants Blood, June 15, 1999; 93(12): 4365 - 4374. [Abstract] [Full Text] [PDF]

				G Nardone, S Staibano, A Rocco, E Mezza, F P D'Armiento, L Insabato, A Coppola, G Salvatore, A Lucariello, N Figura, et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis Gut, June 1, 1999; 44(6): 789 - 799. [Abstract] [Full Text] [PDF]

				L. Aaltonen, P Peltomaki, F. Leach, P Sistonen, L Pylkkanen, J. Mecklin, H Jarvinen, S. Powell, J Jen, Hamilton SR, et al. Clues to the pathogenesis of familial colorectal cancer Science, May 7, 1993; 260(5109): 812 - 816. [Abstract] [PDF]